Yahoo Finance • 16 days ago
Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best up and coming stocks with huge upside potential. On September 9, LifeSci Capital analyst Francois Brisebois reiterated a Buy rating on Centessa Pharmaceuticals and set a price targe... Full story
Yahoo Finance • last month
[Wall Street New York stock exchange stock market] alexsl Centessa Pharmaceuticals (NASDAQ:CNTA [https://seekingalpha.com/symbol/CNTA]) has been rated as Outperform at Oppenheimer, reflecting strong conviction in the company's lead asset,... Full story
Yahoo Finance • 2 months ago
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idi... Full story
Yahoo Finance • 2 months ago
Insights from the Fund's Second Quarter 2025 N-PORT Filing Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) recently submitted its N-PORT filing for the second quarter of 2025, revealing strategic investment decisions made d... Full story
Yahoo Finance • 2 months ago
Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals PLC (NASDAQ:CNTA), a $2.06 billion market cap biotech company, sold 10,000 ordinary shares on July 25, 2025, for $155,598. The shares were sold at prices ranging from... Full story
Yahoo Finance • 2 months ago
Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist. Continue Reading View Comments... Full story
Yahoo Finance • 3 months ago
Centessa Pharmaceuticals PLC (NASDAQ:CNTA) Chief Business Officer Gregory M. Weinhoff sold 10,000 ordinary shares of the company on June 25, 2025, for a total of $138,642. The shares were sold at prices ranging from $13.60 to $14.06. On th... Full story
Yahoo Finance • 3 months ago
Mario Alberto Accardi, President, Orexin Program at Centessa Pharmaceuticals PLC (NASDAQ:CNTA), sold 15,000 ordinary shares of the company on June 24, 2025, for $14.00 each, totaling $210,000. The transaction comes as the stock has shown s... Full story
Yahoo Finance • 3 months ago
Centessa Pharmaceuticals PLC (NASDAQ:CNTA), a biotech company with a market capitalization of $1.69 billion, saw its Chief Executive Officer Saurabh Saha sell 55,000 ordinary shares of the company on June 20, 2025, for a total of $694,826.... Full story
Yahoo Finance • 3 months ago
[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images UBS upgraded Alkermes (NASDAQ:ALKS [https://seekingalpha.com/symbol/ALKS]) to Buy from Neutral on Tuesday, citing prospects for Irish biotech’s orexin 2 receptor (OX2R) ag... Full story
Yahoo Finance • 4 months ago
BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND to initiate a... Full story
Yahoo Finance • 4 months ago
BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that memb... Full story
Yahoo Finance • 5 months ago
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idi... Full story
Yahoo Finance • 5 months ago
We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Centessa Pharmaceuticals plc (NASDAQ:CNTA) stands against other top small cap stocks to buy... Full story
Yahoo Finance • 6 months ago
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopa... Full story
Yahoo Finance • 7 months ago
BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announce... Full story
Yahoo Finance • 2 years ago
Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio IND filing to support clinical development of ANB101 in autoimmune and inflammatory diseases expected in H2 2... Full story
Yahoo Finance • 2 years ago
SerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentationat American Society of Hematology (ASH) Annual Meeting in December 202... Full story
Yahoo Finance • 2 years ago
BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study... Full story
Yahoo Finance • 2 years ago
- Preclinical data demonstrated significant activity at low doses of ORX750 in highly predictive translational models of Narcolepsy Type 1 (NT1) - ORX750 advancing in IND-enabling studies; Clinical proof of concept data planned for 2024... Full story